Last update:

Oncology & Cancer news

Oncology & Cancer

A battle of rafts: How molecular dynamics in CAR T cells explain their cancer-killing behavior

A study published in Science Advances shares new insights into how two of the most common types of chimeric antigen receptor (CAR) T cells kill cancer.

Oncology & Cancer

'Explant' technique predicts a tumor's responsiveness to breast cancer treatment

Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer patients will respond to chemotherapy and antibody-directed cancer treatments.

Medications

New drug for prostate cancer patients in clinical trials

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical ...

Medications

Talquetamab plus teclistamab shows promise in multiple myeloma

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according ...

Oncology & Cancer

New tool puts reproductive risk for BRCA carriers into perspective

"I just wish someone had told me this was a possibility." Kara Maxwell distinctly remembers the moment she heard those words eight years ago from the mother of a child with Fanconi anemia (FA). Maxwell met her at a conference ...

Oncology & Cancer

Study identifies TBK1 as key to overcoming CAR T resistance

Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author ...

Oncology & Cancer

Cell line models identify cause of melanoma with drug resistance

Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known as the most lethal form of skin cancer due to its high rates of metastasis and recurrence. With ...

Oncology & Cancer

Study explores novel therapeutic treatment for glioblastoma

Glioblastoma (GBM) is the most lethal brain tumor, with a median survival rate of merely 12-16 months after diagnosis. Despite surgical, radiation and chemotherapy treatments, the two-year survival rate for GBM patients is ...